Totally missing the points. No measuring methods at the time or produced subsequently have proven good enough for accurate interpretation of progression vs pseudoprogression for PFS and FDA “required” crossover due to leukapheresis procedures which subjected ~90% of patients to an active treatment regimen. Exceptions to adequate and well controlled studies employed. Go Phish!; ). Best wishes.
Market Data 
Markets 
AI
